Q1 2021 Targovax ASA Earnings Call Transcript
Ladies and gentlemen, welcome to the Targovax First Quarter 2021 Presentation. My name is Ãystein Soug, and I'm the CEO of the company. For you today, we have a program, where we will delve into the melanoma data a bit further than we have done before. And to do that, we have our Chief Business Officer, Erik Digman Wiklund with us, and he will take us through the new data in melanoma. Also, we have Torbjørn Furuseth, our Chief Financial Officer, with us today, and he will go through the finances. You can ask questions as we go along, and we will answer them at the end.
But first, let me give you a reminder about who we are and what we're doing. Our lead product candidate is an oncolytic virus called ONCOS-102. And with ONCOS-102, we have stellar efficacy data. We have really solid powerful immune activation data, and we are committed to take this compound further towards the market in combination with a checkpoint inhibitor. We also have an emerging pipeline where we explore novel viruses with new transgenes, new modalities but also mutant RAS
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |